Financials data is unavailable for this security.
View more
Year on year Biotage AB had net income fall -8.21% from 268.00m to 246.00m despite a 19.54% increase in revenues from 1.57bn to 1.87bn.
| Gross margin | 62.67% |
|---|---|
| Net profit margin | 12.08% |
| Operating margin | 16.50% |
| Return on assets | 5.21% |
|---|---|
| Return on equity | 6.85% |
| Return on investment | 6.05% |
More ▼
Cash flow in SEKView more
In 2023, Biotage AB increased its cash reserves by 34.69%, or 153.00m. The company earned 284.00m from its operations for a Cash Flow Margin of 15.17%. In addition the company generated 35.00m cash from investing, though they paid out 142.00m more in financing than they received.
| Cash flow per share | 5.47 |
|---|---|
| Price/Cash flow per share | 29.75 |
| Book value per share | 47.60 |
|---|---|
| Tangible book value per share | 6.86 |
More ▼
Balance sheet in SEKView more
| Current ratio | 1.91 |
|---|---|
| Quick ratio | 1.15 |
| Total debt/total equity | 0.0656 |
|---|---|
| Total debt/total capital | 0.0616 |
More ▼
Growth rates in SEK
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -17.90%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.74% |
|---|---|
| Div growth rate (5 year) | 1.30% |
| Payout ratio (TTM) | 49.81% |
| EPS growth(5 years) | 5.12 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 17.55 |
More ▼
